



11-09-05  
JC06 Rec'd PCT/PTO 08 NOV 2005 PATENT  
ATTORNEY DOCKET NO. 13TP/PCT2/US

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**CERTIFICATE OF MAILING**

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. EY635673560 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[ X ] If checked, two copies of this correspondence are enclosed.

Dawn M. Janelle

Signature

Date of Deposit: Nov 8, 2005

Dawn M. Janelle

Printed name of person mailing correspondence

Applicant: DONG, Zheng Xin	Art Unit: Unknown
Serial No.: 10/553,014	Examiner: Unknown
Filed: Oct. 11, 2005	
Title: SOMATOSTATIN -DOPAMINE CHIMERIC ANALOGS & USES THEREOF	

**INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO  
CHARGE DEPOSIT ACCOUNT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- [ ] under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- [ X ] under 37 CFR 1.97(b), or  
(Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)
- [ ] under 37 CFR 1.97(c) together with either:  
[ ] a Statement under 37 CFR 1.97(e), as checked below, or  
[ ] a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- [ ] under 37 CFR 1.97(d) together with:  
[ ] a Statement under 37 CFR 1.97(e), as checked below, and  
[ ] a Petition under 37 CFR 1.97(d)(2), and  
[ ] a \$130.00 petition fee set forth in 37 CFR 1.17(i).  
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)
- [ ] Applicant requests that the attached IDS and cited reference(s) [ ] be placed in the application filewrapper.  
(Filed after payment of issue fee)
- [ ] Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

- Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of each reference noted thereon.
- Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of selected references noted thereon. As per the change to 37 CFR 1.98(a)(2) published in the September 21, 2004 Federal Register and effective as of October 21, 2004, in which the requirement for a copy of each U.S. Patent or U.S. Patent application publication listed in an IDS has been eliminated regardless of the filing date of the application (unless required by the Office), copies of any United States Patent or Patent Publications are not enclosed.
- Copies of the reference(s) noted on the enclosed form PTO/1449 (N pages, reproduced form) were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [ ], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)). Applicants request that copies of art in U.S. Application Serial No. [ ] cited on the enclosed PTO/1449 form be transferred to the present U.S. Application Serial No. [ ].

Concise Explanation Requirement (non-English references):

- The "concise explanation" requirement for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
- the explanation provided on the attached sheet.
- the explanation provided in the Specification.
- submission of the enclosed International Search Report.
- the enclosed English language abstracts

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Statement Under 37 CFR 1.97(e):

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.


Method of payment:

- A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,  
BIOMEASURE, INCORPORATED

By Pamela C. Ball  
Pamela C. Ball, Agent for Applicant(s)  
Registration No.: 53,963

Dated: 11/8/05  
27 Maple Street  
Milford, Massachusetts 01757  
Phone: (508)478-0144  
Facsimile: (508) 473-3531

			ATTORNEY DOCKET NO. 131P/PCT2/US		APPLICATION NO. 10/553,014		
			APPLICANT DONG, Z. et al.				
			FILING DATE October 11, 2005		GROUP/EXAMINER Unknown/Unknown		
<b>U.S. PATENT DOCUMENTS</b>							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
A	BASU, S. et al., "The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor," Nature Medicine, 2001, 7:569-574.						
B	REUBI, J.C. et al., "Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance," Yale J. Biol. and Med., 1997, 70:471-479.						
C	SAVEANU, A. et al., "Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells," J. Clin. Endo. & Metab., 2002, 87:5545-5552.						
D	TANGBANLUEKAL, L. et al., "Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats," Endocrinology, 1993, 132:2407-2416.						
EXAMINER			DATE CONSIDERED				